Vedolizumab Placebo
Vedolizumab Placebo is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
1
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
0
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)
A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
Clinical Trials (6)
Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)
A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6